SCHEMBL19640883

SCHEMBL19640883

Cc1ccc(S(=O)(=O)N2C3CCC2CNC3)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.58
MCOLN3 Q8TDD5 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
AKR1C3 P42330 1/20 0.49
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
PKM P14618 3/20 0.47
MMP2 P08253 1/20 0.46
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
HSD11B1 P28845 2/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
EBP Q15125 1/20 0.43
DHCR7 Q9UBM7 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13812162 0.87 ACHE (0.68) ACHEMCOLN3L3MBTL1AKR1C3ALDH1A1
SCHEMBL19640887 0.83 PSEN1 (0.57) ACHEAKR1C3ALDH1A1PKMMMP2
SCHEMBL19640864 0.83 ESR1 (0.60) ACHEAKR1C3MMP2CA1CA2
SCHEMBL19640858 0.83 AKR1C3 (0.49) L3MBTL1AKR1C3KDM4EPKMMMP2
SCHEMBL19640837 0.83 AKR1C3 (0.49) ACHEMCOLN3L3MBTL1AKR1C3HSD11B1
SCHEMBL19640791 0.82 ACHE (0.54) ACHEL3MBTL1AKR1C3ALDH1A1KDM4E
SCHEMBL21913505 0.82 ACHE (0.54) ACHEMCOLN3L3MBTL1AKR1C3ALDH1A1
SCHEMBL19640805 0.82 ALDH1A1 (0.55) L3MBTL1AKR1C3ALDH1A1KDM4EPKM
SCHEMBL19640890 0.81 AKR1C3 (0.53) ACHEAKR1C3ALDH1A1MMP2SMN1; SMN2
SCHEMBL19640886 0.79 AKR1C3 (0.52) ACHEAKR1C3ALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464288-B1 [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES Bayer Pharma AG (DE) 2020-12-23 EP disclosed
EP-3464288-B1 [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES Bayer Pharma AG (DE) 2020-12-23 EP disclosed
US-10167293-B2 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-01 US disclosed
US-10167293-B2 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-01 US disclosed
US-20170342082-A1 [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES Bayer Pharma AG (DE) 2017-11-30 US disclosed
US-20170342082-A1 [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES Bayer Pharma AG (DE) 2017-11-30 US disclosed
WO-2017202817-A1 [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL] (1H-1,2,3-TRIAZOL-4-YL)METHANONES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342082-A1 [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES PKD1, PKD2, PDK3 ACHE 4604/4885MCOLN3 947/4885L3MBTL1 3805/4885
US-10167293-B2 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones PKD1, PKD2, PDK3 ACHE 4604/4885MCOLN3 947/4885L3MBTL1 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.